Stocks to Watch: MiMedx Group, Nokia
29 Dezembro 2023 - 8:39PM
Dow Jones News
By Ben Glickman
MiMedx Group said on Friday it received an FDA warning letter
related to the classification of its product Axiofill. The
regulator has reaffirmed that the company's treatment doesn't
qualify as a Section 361 product, meaning it likely requires
pre-market review. Shares fall 6.5% to $8.20 after-hours.
Nokia expects to miss its 2023 financial outlook as
license-renewal discussions stretch into 2024. The company expects
to miss guidance on net sales, comparable operating margin and free
cash flow, and can't provide preliminary financial results for the
quarter because the reporting period hasn't concluded. Shares fall
1.5% to $3.37 after-hours.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 29, 2023 18:24 ET (23:24 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Nokia (NYSE:NOK)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Nokia (NYSE:NOK)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024